Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Epcoritamab-R-GemOx With Consolidative ASCT and Additional Epcoritamab in Relapsed/Refractory Transplant-Eligible DLBCL

NCT07365306 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07365306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07365306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Epcoritamab-R-GemOx With Consolidative ASCT and Additional Epcoritamab in Relapsed/Refractory Transplant-Eligible DLBCL
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
July 27, 2026
Completion date
October 15, 2029
Enrollment
43 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse large b-cell lymphoma, not otherwise specified, recurrent high grade b-cell lymphoma, not otherwise specified, recurrent primary mediastinal large b-cell lymphoma, recurrent transformed indolent b-cell non-hodgkin lymphoma to diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, not otherwise specified, refractory high grade b-cell lymphoma, not otherwise specified, refractory primary mediastinal large b-cell lymphoma, refractory transformed indolent b-cell non-hodgkin lymphoma to diffuse large b-cell lymphoma